Samsung Biologics breaks ground on 'super plant'

By The Science Advisory Board staff writers

November 18, 2020 -- Samsung Biologics broke ground on the construction of its biopharma manufacturing facility Plant 4 in Incheon, South Korea during a virtual ceremony.

It has been dubbed the "super plant" because the new, multistory 238,000-sq-mt facility will boast 256,000 L of total manufacturing capacity. Once completed, it will be the largest biopharmaceutical manufacturing facility in the world, according to the company.

Samsung Biologics Plant 4 Groundbreaking Ceremony. Image courtesy of Samsung Biologics.
Samsung Biologics Plant 4 groundbreaking ceremony. Image courtesy of Samsung Biologics.

With this plant, Samsung Biologics anticipates being responsible for a third of the total global bio-contract manufacturing organization capacity, offering a combined sum of 620,000 L from a single site. Plant 4 will feature a modular design, allowing for certain parts of the facility to begin manufacturing by the end of 2022. The plant is expected to be fully operational in 2023.

Lilly partners with Samsung Biologics to manufacture COVID-19 antibodies
Eli Lilly and Samsung Biologics have signed a long-term partnership for manufacturing of Lilly's COVID-19 antibody therapies.
Samsung Biologics partners on antibody development, manufacturing
Samsung Biologics has announced that its contract development and manufacturing organization services have been selected by two companies for their antibody...
Samsung Biologics, BioEleven partner on cancer immunotherapy
Samsung Biologics has entered into a strategic partnership with BioEleven to develop and manufacture BN-101A, a third-generation immunotherapy to treat...
Samsung Biologics, Kanaph Therapeutics partner on retinal disease therapy
Samsung Biologics and Kanaph Therapeutics are partnering on the development of KNP-301, a bispecific Fc fusion protein to treat retinal diseases.
Samsung Biologics, AstraZeneca ink manufacturing deal
Samsung Biologics and AstraZeneca have signed a $330.8 million long-term supply agreement.

Copyright © 2020

Interphex 2021
October 19-21
New York City, New York United States
Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter